MAP Kinases and Prostate Cancer
Author(s) -
Gonzalo RodríguezBerriguete,
Benito Fraile,
Pilar Martínez-Onsurbe,
Gabriel Olmedilla,
Ricardo Paniagua,
Mar Royuela
Publication year - 2011
Publication title -
journal of signal transduction
Language(s) - English
Resource type - Journals
eISSN - 2090-1739
pISSN - 2090-1747
DOI - 10.1155/2012/169170
Subject(s) - p38 mitogen activated protein kinases , mapk/erk pathway , medicine , apoptosis , kinase , cancer research , prostate cancer , programmed cell death , prostate , tumor promotion , cell growth , cancer , signal transduction , radioresistance , mitogen activated protein kinase , microbiology and biotechnology , biology , radiation therapy , biochemistry , carcinogenesis
The three major mitogen-activated protein kinases (MAPKs) p38, JNK, and ERK are signal transducers involved in a broad range of cell functions including survival, apoptosis, and cell differentiation. Whereas JNK and p38 have been generally linked to cell death and tumor suppression, ERK plays a prominent role in cell survival and tumor promotion, in response to a broad range of stimuli such as cytokines, growth factors, ultraviolet radiation, hypoxia, or pharmacological compounds. However, there is a growing body of evidence supporting that JNK and p38 also contribute to the development of a number of malignances. In this paper we focus on the involvement of the MAPK pathways in prostate cancer, including the less-known ERK5 pathway, as pro- or antitumor mediators, through their effects on apoptosis, survival, metastatic potential, and androgen-independent growth.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom